These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21485727)

  • 41. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.
    Kroll R; Seidman L; Ricciotti N; Howard B; Weiss H
    Eur J Contracept Reprod Health Care; 2015; 20(4):249-58. PubMed ID: 25522805
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
    Goebelsmann U; Hoffman D; Chiang S; Woutersz T
    Contraception; 1986 Oct; 34(4):341-51. PubMed ID: 3096634
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
    Ankrom W; Jackson Rudd D; Zhang S; Fillgrove KL; Gravesande KN; Matthews RP; Brimhall D; Stoch SA; Iwamoto MN
    J Int AIDS Soc; 2021 Dec; 24(12):e25858. PubMed ID: 34935295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium.
    Franceschini SA; Vieira CS; Martins WP; França JB; Ferriani RA
    Contraception; 2013 Jun; 87(6):766-72. PubMed ID: 23102798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of a new triphasic oral contraceptive in private practice.
    Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
    Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives.
    Nielsen CH; Poulsen HK; Teisner B; Thorsen P; Hau J; Westergaard JG
    Eur J Obstet Gynecol Reprod Biol; 1993 Sep; 51(1):63-71. PubMed ID: 7506680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
    Gaussem P; Alhenc-Gelas M; Thomas JL; Bachelot-Loza C; Remones V; Ali FD; Aiach M; Scarabin PY
    Thromb Haemost; 2011 Mar; 105(3):560-7. PubMed ID: 21225090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of two oral contraceptive combinations, 0.125 mg desogestrel + 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol on the adrenal function of healthy female volunteers.
    Ruokonen A; Lund L; Nummi S; Alapiessa U; Viinikka L
    Eur J Obstet Gynecol Reprod Biol; 1982 Jun; 13(4):259-65. PubMed ID: 6214438
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.
    Sriprasert I; Stanczyk FZ; Archer DF
    Expert Opin Pharmacother; 2015; 16(12):1901-9. PubMed ID: 26194214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels.
    Kuhl H; Gahn G; Romberg G; März W; Taubert HD
    Contraception; 1985 Jun; 31(6):583-93. PubMed ID: 2931247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT; Zimmerman Y; Laan E; Termeer HMM; Appels N; Albert A; Fauser BCJM; Thijssen JHH; van Lunsen RHW
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of two phasic oral contraceptives on hemostasis and platelet function.
    Weinges KF; Wenzel E; Hellstern P; Geurts TB; Dieben TO
    Adv Contracept; 1995 Sep; 11(3):227-37. PubMed ID: 8533625
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lansoprazole does not affect the bioavailability of oral contraceptives.
    Fuchs W; Sennewald R; Klotz U
    Br J Clin Pharmacol; 1994 Oct; 38(4):376-80. PubMed ID: 7833230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol.
    Creinin MD; Lippman JS; Eder SE; Godwin AJ; Olson W
    Contraception; 2002 Sep; 66(3):147-52. PubMed ID: 12384201
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
    Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
    Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormonal treatment for bleeding irregularities in Norplant implant users.
    Alvarez-Sanchez F; Brache V; Thevenin F; Cochon L; Faundes A
    Am J Obstet Gynecol; 1996 Mar; 174(3):919-22. PubMed ID: 8633669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia.
    Koh SC; Singh K
    J Thromb Haemost; 2007 Jan; 5(1):133-8. PubMed ID: 17010149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.